JAK2 and Thrombocytopenia: Since pathophysiologically thrombocytopenia is attributed to JAK2 inhibitors (Figure 1), due to mediation of thrombopoietin (TPO) signaling via JAK2, and abrocitinib at the doses used should relatively selectively inhibit JAK1, this adverse drug effect was further investigated by the manufacturer in mechanistic models.